secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2023-05-11T23:59:59+00:00
Accession:  0000950170-23-021359
Event type: other
Sentiment:  neutral
Materiality: 0.10
Item codes: 5.03, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics amends bylaws for universal proxy rules and enhanced disclosure
--------------------------------------------------------------------------------

- Board approved amended and restated bylaws effective May 9, 2023.
- Amendments require stockholders nominating directors to comply with SEC Rule 14a-19 universal proxy rules.
- Enhanced disclosure requirements for director nominations and business proposals by stockholders.
- Stockholders soliciting proxies must use a proxy card color other than white; white reserved for Board.
- Eliminated requirement to make stockholder list available during meetings, consistent with Delaware law.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023021359/0000950170-23-021359-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000095017023021359/vktx-20230509.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-021359

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer